Asia Pacific Sterile Injectables Cdmo Market Size & Outlook
Asia Pacific sterile injectables cdmo market, 2018-2030 (US$M)
Asia Pacific sterile injectables cdmo market highlights
- The Asia Pacific sterile injectables cdmo market generated a revenue of USD 1,000.3 million in 2023.
- The market is expected to grow at a CAGR of 11% from 2024 to 2030.
- In terms of segment, small molecule was the largest revenue generating molecule type in 2023.
- Small Molecule is the most lucrative molecule type segment registering the fastest growth during the forecast period.
Asia Pacific data book summary
| Market revenue in 2023 | USD 1,000.3 million |
| Market revenue in 2030 | USD 2,079.0 million |
| Growth rate | 11% (CAGR from 2023 to 2030) |
| Largest segment | Small molecule |
| Fastest growing segment | Small Molecule |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Small Molecule |
| Key market players worldwide | Boehringer Ingelheim, Baxter International Inc, Vetter Pharma-Fertigung, Recipharm, Fresenius Kabi, Ajinomoto, PCI Pharma Services, IDT Biologika, Alcami, Fareva, Eurofins Scientific SE, Siegfried Holding AG |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 25.4% of the global sterile injectables cdmo market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 2,079.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Sterile Injectables CDMO Market Scope
Sterile Injectables CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific sterile injectables cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to sterile injectables cdmo market will help companies and investors design strategic landscapes.
Small molecule was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Asia Pacific sterile injectables cdmo market based on small molecule covering the revenue growth of each sub-segment from 2018 to 2030.
Growth in the Asia Pacific market can be attributed to the increasing demand for injectable drugs, advancements in biotechnology, the rising prevalence of chronic diseases, and favorable government policies.
The region has witnessed increasing cases of chronic diseases, such as diabetes and cardiovascular diseases, which necessitate effective treatment options like injectable medications. Moreover, several regulatory changes in the Asia Pacific are attracting several CDMOs to expand their services in this market.
The new primary evaluation approach would enable faster and more efficient drug approvals in Hong Kong. This would benefit CDMOs by reducing approval timelines, enabling quicker entry into the country market, accelerating the launch of new injectable products, and enhancing the competitiveness of CDMOs.
Reasons to subscribe to Asia Pacific sterile injectables cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific sterile injectables cdmo market databook
-
Our clientele includes a mix of sterile injectables cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific sterile injectables cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific sterile injectables cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific sterile injectables cdmo market
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
